Key result
Although urinary NT-proBNP correlates with serum values, robust evidence is still needed to establish its role in monitoring and predicting bronchiolitis severity.
Why the study?
Does urinary NT-proBNP predict bronchiolitis severity in infants?
Does urinary NT-proBNP predict bronchiolitis severity in infants?
Answers are grounded in this paper and cite their sources.
This letter highlights the need for robust evidence before using urinary or serum NT-proBNP to predict bronchiolitis severity, given confounding factors like inflammation and potential subclinical cardiac involvement.
To The Editor, Bronchiolitis is an acute viral respiratory illness and one of the most common causes of hospitalization in infants. The diagnosis and monitoring of bronchiolitis are mainly clinical, and investigation has a very limited role. Reliable biomarkers to predict the complications and the severity of illness are an area of active research. We read the recent article by Rodríguez‐González et al. which has addressed this important aspect, and we applaud the authors. However, we would like to highlight a few points to bring more clarity to this issue. The authors have tried to establish the role of urinary N‐terminal pro‐brain natriuretic peptide (NT‐proBNP) concentrations in the prediction of the severity of bronchiolitis as a surrogate marker of serum NT‐proBNP, and they observed a strong correlation between them. However, there is no established role of serum NT‐proBNP itself in predicting the development of severe bronchiolitis without cardiac involvement. Cohen et al. used serum NT‐proBNP levels in children with respiratory distress and found no significant difference in NT–proBNP levels between respiratory distress due to pulmonary disease without cardiac involvement and controls. Another study by Jensen et al. showed a higher serum NT‐proBNP/BNP ratio in patients with raised inflammatory markers. They concluded that NT‐proBNP could overestimate the severity of underlying illness. Bronchiolitis is a state of acute inflammation resulting in increased serum inflammatory markers, including NT‐proBNP. This can be a significant confounding factor in predicting bronchiolitis severity. Urinary NT‐proBNP has been assessed as a surrogate marker of serum NT‐proBNP values in children with congenital heart diseases (CHDs). Muller et al. found a good correlation between urinary and serum values. They concluded that spot urine samples could be used instead of a serum sample for NT‐proBNP estimation. However, there is a need for further studies to establish its role as a potential biomarker to direct clinical decisions in children with CHDs. Similarly, urinary NT‐proBNP has been evaluated in children with lower respiratory tract infection (LRTI) to predict the clinical severity and need for hospitalization. The study did not find any significant difference in urinary NT‐proBNP values between children with LRTI, children requiring hospitalization, and the control group; hence found to be non‐valuable in predicting the severity of illness. In addition, a study by Sahingozlu et al. observed that serum BNP was significantly different between cardiac failure, isolated bronchiolitis, and the control group; however, BNP level was not significantly correlated with the severity of bronchiolitis. In the current study, only 5 out of 17 children had a BROSJOD (bronchiolitis score of Sant Joan de Deu) score > 10, which corresponds to severe illness. Moreover, only 4 out of 17 children had higher NT‐proBNP levels (Z‐log‐NT‐proBNP > 1.96). If the authors had included only severe bronchiolitis cases, possibly more infants might have raised NT‐proBNP. Furthermore, whether this raised NT‐proBNP level was secondary to cardiac involvement could have been addressed by evaluating these four infants with echocardiography and cardiac biomarkers. However, echocardiography was performed only in children who required inotropic support. Therefore, it would be difficult to conclude that this high level of NT‐proBNP is due to isolated severe bronchiolitis. In addition, including healthy infants as control could have overcome these confounding factors. In conclusion, though urinary NT‐proBNP may be significantly correlated with its serum values, there is a need of the hour to establish robust evidence for serum NT‐proBNP in monitoring and predicting bronchiolitis severity.
No takes yet. Share an insight, caveat, or question.
Rajvanshi et al. (2023) conducted a letter in Bronchiolitis (n=17). Urinary NT-proBNP was evaluated on Prediction of bronchiolitis severity. Although urinary NT-proBNP correlates with serum values, robust evidence is still needed to establish its role in monitoring and predicting bronchiolitis severity.
Synapse has enriched 10 related papers. Consider them for comparative context: